Clinical review of a long-acting, injectable formulation of risperidone

Clinical Therapeutics

Volumn 26, Issue 12, 2004, Pages 1994-2002

  Knox, Erin Danielle ^a   Stimmel, Glen L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Depot antipsychotic drugs; Long acting risperidone; Risperdal Consta; Risperidone

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; HYPNOTIC SEDATIVE AGENT; LONG ACTING DRUG; MICROSPHERE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROLACTIN; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ANXIETY DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DATA ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HEADACHE; HUMAN; HYPERKINESIA; IMMEDIATE TYPE HYPERSENSITIVITY; INFLAMMATION; INJECTION PAIN; INJECTION SITE REACTION; INSOMNIA; MAINTENANCE THERAPY; MENSTRUAL IRREGULARITY; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; PAIN; PARKINSONISM; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; STEADY STATE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 14844364327     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.12.009     Document Type: Article

References (27)

1. Marder SR Overview of partial compliance J Clin Psychiatry 64 Suppl 16 2003 3 9
2. Glazer WM, and Kane JM Depot neuroleptic therapy: An underutilized option J Clin Psychiatry 53 1992 426 433
3. Bhanji NH, Chouinard G, and Margolese HC A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia Eur Neuropsychopharmacol 14 2004 87 92
4. Ereshefsky L, and Mascarenas CA Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics J Clin Psychiatry 64 Suppl 16 2003 18 23
5. Livingston MG Risperidone Lancet 343 1994 457 460
6. Cohen LJ Risperidone Pharmacotherapy 14 1994 253 265
7. Marder SR, and Meibach RC Risperidone in the treatment of schizophrenia Am J Psychiatry 151 1994 825 835
8. Byerly MJ, and DeVane CL Pharmacokinetics of clozapine and risperidone: A review of recent literature J Clin Psychopharmacol 16 1996 177 187
9. Schooler NR Relapse and rehospitalization: Comparing oral and depot antipsychotics J Clin Psychiatry 64 Suppl 16 2003 14 17
10. Chouinard G, Annable L, and Campbell W A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia J Clin Psychopharmacol 9 1989 247 253
11. Pereira S, and Pinto R A survey of the attitudes of chronic psychiatric patients living in the community toward their medication Acta Psychiatr Scand 95 1997 464 468
12. Gerlach J Oral versus depot administration of neuroleptics in relapse prevention Acta Psychiatr Scand Suppl 382 1994 28 32
13. [published correction appears in N Engl J Med. 2002;346:1424] Csernansky JG, Mahmoud R, Brenner R Risperidone-USA-79 Study Group A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia N Engl J Med 346 2002 16 22
14. [published correction appears in Am J Psychiatry. 2002;159:514]? Dolder CR, Lacro JP, Dunn LB, and Jeste DV Antipsychotic medication adherence: Is there a difference between typical and atypical agents Am J Psychiatry 159 2002 103 108
15. Velligan DI, Lam F, Ereshefsky L, and Miller AL Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications Psychiatr Serv 54 2003 665 667
16. Kane JM, Eerdekens M, and Lindenmayer JP Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic Am J Psychiatry 160 2003 1125 1132
17. Chue P, Eerdekens M, and Augustyns B Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets Poster presented at: 11th Biennial Winter Workshop on Schizophrenia Davos, Switzerland February 23, 2002-March 1, 2002
18. Jones R, Lasser RA, Bossie CA, and Conley RR Clinical improvement with long-acting risperidone in patients previously receiving oral olanzapine Poster presented at: 156th Annual Meeting of the American Psychiatric Association San Francisco, California May 17-22, 2003
19. Rodriguez S, Bossie C, and Lasser R Long-acting injectable risperidone in hospital inpatients with schizophrenia Poster presented at: 156th Annual Meeting of the American Psychiatric Association San Francisco, California May 17-22, 2003
20. Turner M, Eerdekens M, Jacko M, and Eerdekens E Long-acting injectable risperidone (Risperdal Consta): Safety and efficacy in stable patients switched from conventional depot antipsychotics Presented at: 43rd Annual New Clinical Drug Evaluation Unit Meeting Boca Raton, Florida May 27-30, 2003
21. [published correction appears in J Clin Psychiatry. 2004;65:1150] Nasrallah HA, Duchesne I, and Mehnert A Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone J Clin Psychiatry 65 2004 531 536
22. Fleischhacker WW, Eerdekens M, and Karcher K Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic J Clin Psychiatry 64 2003 1250 1257
23. Canuso CM, Bossie CA, Lasser RA, and Gharabawi G Reduced serum prolactin levels after treatment with long-acting risperidone Poster presented at: 156th Annual Meeting of the American Psychiatric Association San Francisco, California May 17-22, 2003
24. [package insert] Risperdal Consta (Risperidone) long-acting injection 2004 Janssen Pharmaceutica Products LP St Louis, Mo
25. Kelleher JP, Centorrino F, Albert MJ, and Baldessarini RJ Advances in atypical antipsychotics for the treatment of schizophrenia: New formulations and new agents CNS Drugs 16 2002 249 261
26. Eerdekens M, Rasmussen M, and Vermeulen A Kinetics and safety of a novel risperidone depot formulation Poster presented at: 23rd Collegium Internationale NeuroPsychopharmacologicum Congress Brussels, Belgium July 9-13, 2000
27. Marder SR, Conley R, and Ereshefsky L Clinical guidelines: Dosing and switching strategies for long-acting risperidone J Clin Psychiatry 64 Suppl 16 2003 41 46